Valeant CEO Sells- Michael J. Pearson, CEO at Valeant Pharmaceuticals (NYSE:VRX) sold 1,297,399 shares at $78.48. The total value of the transaction was approximately $101.83 million.
$8 green tomorrow
Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA
Anavex Life Sciences Corp.
NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73. Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.
“Working with a highly vulnerable patient population, the Company is proceeding in a rational, step-wise process. Armed with the necessary data from the Phase 2a study to optimally design future trials, we lookforward to expanding our development program,” said Kristina M. Capiak, Vice President Regulatory Affairs of Anavex.
Ocera Therapeutics Rises on Positive Results
24/7 Wall St. By Chris Lange
For some background: OCR-002 is an ammonia scavenger and has been granted orphan drug designation
and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease
What makes Anavex such an exciting story is the Company is not focused on treating the symptoms of Alzheimer’s but rather is focused on the root cause which is believed to be protein misfolding. AVXL’s Anavex 2-73 can work as an agonist for the sig-1R receptor that is behind protein misfolding. What is even more exciting is the fact that the same mechanism can work in Parkinson’s and Huntington diseases.
AVXL lead drug candidates, Anavex 2-73 and Anavex PLUS, a combination of Anavex 2-73 and donepezil (Aricept®) are currently being evaluated in a Phase 2a clinical trial for Alzheimer’s disease and continue to be the major catalyst here.
In earlier preclinical studies, Anavex 2-73 showed potential to halt and/or reverse Alzheimer’s disease.Additionally, positive preclinical data reveals the potential for Anavex 2-73 as a platform drug to treat additional CNS disorders, including epilepsy.
Good DD -Adam F never impressed so that is huge.
Sentiment: Strong Buy
8 Fresh Analyst Picks Called to Rise 50% to 100% ( BLUE )
By Jon C. Ogg
Wall Street Journal
[$$] CVS, Express Scripts Cut Off Philidor, Pharmacy Used by Valeant